Mergers & Acquisitions ·
MiMedx Group, Inc. reported a second quarter 2026 net loss of $15 million on net sales of $64 million, a 35%…
MDXGMimedx Group, Inc.
MiMedx Group, Inc. reported a second quarter 2026 net loss of $15 million on net sales of $64 million, a 35% year-over-year decline driven by a 61% drop in Wound segment revenue due to Medicare reimbursement changes. Surgical sales grew 15% to $39 million. The company announced a definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in enterprise value, paying $33 per share in cash and 0.4735 shares of MiMedx stock per Sanara share. The transaction is financed by a new $300 million term loan from Hayfin Capital Management and existing cash, with expected closing by year-end 2026 subject to regulatory approvals and shareholder consent. MiMedx reiterated its full-year 2026 net sales guidance of $260-290 million. The company operates in the healthcare sector, providing placental-derived healing solutions for wound care and surgical applications.